Literature DB >> 23977535

Biomarkers and prognostic factors for mesothelioma.

Harvey I Pass1.   

Abstract

Entities:  

Year:  2012        PMID： 23977535      PMCID： PMC3741796          DOI： 10.3978/j.issn.2225-319X.2012.10.04

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN： 2225-319X


× No keyword cloud information.
  57 in total

1.  Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.

Authors:  Ritu R Gill; William G Richards; Beow Y Yeap; Shin Matsuoka; Andrea S Wolf; Victor H Gerbaudo; Raphael Bueno; David J Sugarbaker; Hiroto Hatabu
Journal:  AJR Am J Roentgenol       Date:  2012-02       Impact factor: 3.959

Review 2.  Malignant pleural mesothelioma: the standard of care and challenges for future management.

Authors:  Jan P van Meerbeeck; Arnaud Scherpereel; Veerle F Surmont; Paul Baas
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-13       Impact factor: 6.312

3.  Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.

Authors:  Steven Chuan-Hao Kao; Nicola Armstrong; Bridget Condon; Kim Griggs; Brian McCaughan; Sarah Maltby; Alan Wilson; Douglas W Henderson; Sonja Klebe
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

4.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

5.  Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.

Authors:  Shuko Nojiri; Kenichi Gemba; Keisuke Aoe; Katsuya Kato; Takuhiro Yamaguchi; Tsugumichi Sato; Kiyoshi Kubota; Takumi Kishimoto
Journal:  Jpn J Clin Oncol       Date:  2010-08-26       Impact factor: 3.019

6.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

7.  Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.

Authors:  Tristan D Yan; Michael Boyer; Mo Mo Tin; Daniel Wong; Catherine Kennedy; Jocelyn McLean; Paul G Bannon; Brian C McCaughan
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-09       Impact factor: 5.209

8.  Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Authors:  Joachim Schneider; Hans Hoffmann; Hendrik Dienemann; Felix J F Herth; Michael Meister; Thomas Muley
Journal:  J Thorac Oncol       Date:  2008-11       Impact factor: 15.609

9.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

10.  Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma.

Authors:  V H Gerbaudo; S Britz-Cunningham; D J Sugarbaker; S T Treves
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139
View more
  12 in total

1.  The challenge of prognostic markers in pleural mesothelioma.

Authors:  Andrea Imperatori; Massimo Castiglioni; Lorenzo Mortara; Elisa Nardecchia; Nicola Rotolo
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.

Authors:  R Berardi; M Caramanti; I Fiordoliva; F Morgese; A Savini; S Rinaldi; M Torniai; M Tiberi; C Ferrini; M Castagnani; F Rovinelli; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2014-08-21       Impact factor: 3.603

3.  Expression and significance of miRNA-21 and BTG2 in lung cancer.

Authors:  Qing Sun; Meng Hang; Xuedan Guo; Wenlong Shao; Guangqiao Zeng
Journal:  Tumour Biol       Date:  2013-07-16

4.  MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Authors:  Michaela B Kirschner; Yuen Yee Cheng; Nicola J Armstrong; Ruby C Y Lin; Steven C Kao; Anthony Linton; Sonja Klebe; Brian C McCaughan; Nico van Zandwijk; Glen Reid
Journal:  Mol Oncol       Date:  2014-12-02       Impact factor: 6.603

5.  Reproducibility of histological subtyping of malignant pleural mesothelioma.

Authors:  Luka Brčić; Marko Jakopović; Iva Brčić; Vlasta Klarić; Milan Milošević; Ana Sepac; Miroslav Samaržija; Sven Seiwerth
Journal:  Virchows Arch       Date:  2014-10-10       Impact factor: 4.064

6.  Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.

Authors:  Yunkai Yu; Bríd M Ryan; Anish Thomas; Betsy Morrow; Jingli Zhang; Zhigang Kang; Adriana Zingone; Masanori Onda; Raffit Hassan; Ira Pastan; Liang Cao
Journal:  J Appl Lab Med       Date:  2018-09

7.  Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.

Authors:  L Gutierrez-Sainz; P Cruz; S Martinez-Recio; O Higuera; M I Esteban-Rodriguez; F Arias-Lotto; R A Gonzalez; J De Castro-Carpeño
Journal:  Clin Transl Oncol       Date:  2021-04-10       Impact factor: 3.405

8.  MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.

Authors:  Bijing Mao; He Xiao; Zhimin Zhang; Dong Wang; Ge Wang
Journal:  Mol Med Rep       Date:  2015-07-07       Impact factor: 2.952

9.  Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.

Authors:  Harvey I Pass; Dorothy Giroux; Catherine Kennedy; Enrico Ruffini; Ayten K Cangir; David Rice; Hisao Asamura; David Waller; John Edwards; Walter Weder; Hans Hoffmann; Jan P van Meerbeeck; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

10.  Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Authors:  Christian Geltner; Peter Errhalt; Bernhard Baumgartner; Gerhard Ambrosch; Barbara Machan; Josef Eckmayr; Thomas Klikovits; Mir Alireza Hoda; Helmut Popper; Walter Klepetko
Journal:  Wien Klin Wochenschr       Date:  2016-09-12       Impact factor: 1.704
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.